



Get Access

Share

Export

Current Opinion in Psychology Volume 14, April 2017, Pages 78-83

Cannabinoids as therapeutic for PTSD

Mallory JE Loflin ¹, Kimberly A Babson ¹, Marcel O Bonn-Miller ^{1, 2, 3, 4}

⊞ Show more

https://doi.org/10.1016/j.copsyc.2016.12.001

Get rights and content

Highlights

- Neurobiological research indicates cannabis as possible pharmacological intervention for PTSD.
- CBD and THC + CBD modulate fear memory in rodents.
- Experimental data suggest CBD has acute anti-depressive and anxiolytic effects.
- Data suggest THC reduces nightmares and OSA, while THC + CBD could reduce insomnia.
- Randomized placebo-controlled human trials of cannabinoids for PTSD are underway.

Limited efficacy for current pharmacotherapy for PTSD indicates that improved pharmacological treatments are needed. Neurobiological research points to cannabinoids as possible therapeutic agents of interest. Moreover, observational reports indicate that there is growing popular interest in therapeutic use of cannabinoids for the alleviation of trauma symptoms. The aim of this review was to present an up-to-date look at current research on the possible therapeutic value of cannabinoids for PTSD. Experimental, preclinical, and clinical findings are discussed.



Previous

Next



Special issue articles

Recommended articles

Citing articles (9)

Published by Elsevier Ltd.



ELSEVIER About ScienceDirect Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2019 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.

